期刊
CELL REPORTS
卷 22, 期 10, 页码 2541-2549出版社
CELL PRESS
DOI: 10.1016/j.celrep.2018.02.049
关键词
-
类别
资金
- Bloomington Drosophila Stock Center [NIH P40OD018537]
- Drosophila Genomics Resource Center [NIH 2P40OD010949]
- Transgenic RNAi Project (TRiP) at Harvard Medical School [NIH/NIGMS R01-GM084947]
- Spanish Ministry of Economy and Competitiveness [BES-2015-073796, BFU2015-64239-R]
- Hungarian Scientific Research Foundation (OTKA) [PD-121193, 109330]
- Hungarian Brain Research Program [KTIA_NAP_13-2-2014-0007]
- European Commission (CancerPathways'') [FP7-HEALH-F22-2008-201666]
- Fundacion Botin
- Generalitat Valenciana [PROMETEO/2017/146]
- Fundacion Espanola Contra el Cancer (AECC) [CICPF16001DOMI]
- Spanish State Research Agency, through the Severo Ochoa'' Program for Centers of Excellence in RD [SEV-2013-0317]
The PI3K/Akt signaling pathway, Notch, and other oncogenes cooperate in the induction of aggressive cancers. Elucidating how the PI3K/Akt pathway facilitates tumorigenesis by other oncogenes may offer opportunities to develop drugs with fewer side effects than those currently available. Here, using an unbiased in vivo chemical genetic screen in Drosophila, we identified compounds that inhibit the activity of proinflammatory enzymes nitric oxide synthase (NOS) and lipoxygenase (LOX) as selective suppressors of Notch-PI3K/Akt cooperative oncogenesis. Tumor silencing of NOS and LOX signaling mirrored the antitumor effect of the hit compounds, demonstrating their participation in Notch-PI3K/Akt- induced tumorigenesis. Oncogenic PI3K/Akt signaling triggered inflammation and immunosuppression via aberrant NOS expression. Accordingly, activated Notch tumorigenesis was fueled by hampering the immune response or by NOS overexpression to mimic a protumorigenic environment. Our lead compound, the LOX inhibitor BW B70C, also selectively killed human leukemic cells by dampening the NOTCH1-PI3K/AKT-eNOS axis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据